Galvani E, Mundra P, Valpione S, et al. Low tumour heterogeneity but not mutational burden correlates with response to anti-PD-1 treatment in a mouse model of melanoma. SMR 2017, abstract SMR4-04.
Adjuvant dabrafenib plus trametinib bij stadium III-melanoom: 10 jaar follow-up
aug 2024 | Dermato-oncologie